ATANU GHORAI

About

Currently, I am fostering and leading a young team in the Neuro-Oncology Program at MSCTR to carry out clinically relevant projects in CNS tumors (mainly Glioblastoma). The aim is to understand its pathogenesis and treatment response/therapy resistance. Using multi-omics approaches and biochemical studies (at the cellular and molecular levels), I am trying to identify and develop novel therapeutics and diagnostics for better patient outcomes.

Employment

• Mazumdar Shaw Medical Foundation Senior Research Scientist
  2023 - Present
• Mazumdar Shaw Medical Foundation Research Scientist
  2021 - 2023
• Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre ACTREC Post-Doctoral Fellow
  2019 - 2021
• Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre National Post-Doctoral Fellow (NPDF), DST-SERB
  2017 - 2019
• Tata Institute of Fundamental Research Post-Doctoral Visiting Fellow
  2015 - 2017

Education

• University of Kalyani PhD
  ? - 2015
• University of Kalyani MSc
  ? - 2007
• Vidyasagar University BSc
  ? - 2005

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Hypoxia-Induced DNA Damage Response and Genomic Instability Dictate Cancer Treatment Response
  Hypoxia and Tumor Microenvironment 2025 DOI: 10.1007/978-981-96-1016-7_4
  +Save
• Biphasic DNA damage and non-canonical replication stress response govern radiation-induced senescence in glioblastoma
  Journal of Cell Science 2024 DOI: 10.1242/jcs.261844
  +Save
• First person – Atanu Ghorai
  Journal of Cell Science 2024 DOI: 10.1242/jcs.263715
  +Save
• PARP-1 negatively regulates nucleolar protein pool and mitochondrial activity: a cell protective mechanism
  Genes and Environment 2024 DOI: 10.1186/s41021-024-00312-w
  +Save
• 14-3-3ζ negatively regulates mitochondrial biogenesis in GBM residual cells.
  Heliyon 2021 DOI: 10.1016/j.heliyon.2021.e08371
  +Save
• Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.
  Neuro-oncology 2020 DOI: 10.1093/neuonc/noaa128
  +Save
• Metabolic rewiring in drug resistant cells exhibit higher OXPHOS and fatty acids as preferred major source to cellular energetics.
  Biochimica et biophysica acta. Bioenergetics 2020 DOI: 10.1016/j.bbabio.2020.148300
  +Save
• Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence.
  Cancer letters 2020 DOI: 10.1016/j.canlet.2020.06.023
  +Save
• Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report.
  Cellular oncology (Dordrecht) 2018 DOI: 10.1007/s13402-018-0411-7
  +Save
• PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells.
  Radiation oncology (London, England) 2016 DOI: 10.1186/s13014-016-0703-x
  +Save